PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.

[1][2] Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.